What are the effects and indications of talazoparib (Talzenna)?

Talazoparib, also known as Talzenna, is a rising star in the field of cancer treatment. Its unique efficacy and potential are gradually attracting global attention. This oral polyADP-ribose polymerase (PARP) inhibitor has demonstrated extraordinary abilities in the process of DNA damage repair, providing new treatment possibilities for cancer patients.

The core mechanism of talazoparib is that it can accurately block the activity of PARP enzyme and firmly lock PARP at the damaged site of DNA, thereby effectively inhibiting the growth of cancer cells and promoting the apoptosis of cancer cells. This unique mechanism makes talazoparib show great potential in the field of cancer treatment.

Talazoparib has achieved remarkable results in the treatment of breast cancer. It is approved by many countries around the world for the treatment of adult patients with locally advanced or metastatic breast cancer who carry deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutations and who are human epidermal growth factor receptor 2 (HER2) negative. As a once-daily monotherapy, talazoparib offers a new treatment option and more hope for breast cancer patients.

In addition to breast cancer, talazoparib has also shown great potential in the treatment of prostate cancer. In recent years, it has been approved by the United States for use in combination with Xtandi (enzalutamide) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations. This combination therapy not only provides patients with more treatment options, but also further improves the treatment effect and gives patients a better chance of survival.

The emergence of talazoparib has undoubtedly brought new treatment hope to cancer patients. Its unique mechanism of action, significant efficacy and relatively safe treatment make talazoparib one of the important drugs in the field of cancer treatment.

However, it is worth noting that the price of talazoparib is relatively high. The original drug Talazoparib produced by Pfizer is available in two different specifications on the market. The 0.25 mg * 30 tablets is priced at more than 18,000 yuan, while the higher dose 1 mg * 30 tablets is priced at nearly 50,000 yuan. For patients with limited financial resources, this is undoubtedly a heavy burden. However, there are still some options for generic drugs in the international market, such as the Lao element version of generic drugs, which are relatively more affordable and provide patients with another viable option. However, patients must choose formal channels when purchasing to ensure the quality and safety of drugs.